Business Context and Reporting Period
Company: Lucid Diagnostics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 4, 2025
Event: The Company entered into a placement agency agreement and subscription agreements for a proposed offering of common stock.
Key Financial Metrics
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Shares Issued: 13,939,331 shares of common stock.
- Purchase Price: $1.10 per share.
- Gross Proceeds: Approximately $15.3 million.
- Estimated Net Proceeds: Approximately $14.5 million (after fees and expenses).
- Placement Agent Fee: 7.0% of gross proceeds from shares introduced by the agent.
- Financial Advisor Fee: $300,000.
- Legal Expense Reimbursement: Up to $50,000.
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change is the execution of a private placement offering. The Company has secured commitments from investors to purchase approximately $15.3 million in equity. The offering is expected to close on or about March 5, 2025, subject to customary closing conditions.
Guidance, Outlook, and Risks
Outlook: The Company intends to utilize the net proceeds of approximately $14.5 million to fund its operations and strategic initiatives, though specific allocation details are not provided in this text.
Risks and Contingencies: The closing of the offering is contingent upon customary conditions. The Company has agreed to indemnify the placement agent against certain liabilities under the Securities Act of 1933. The offering is being conducted pursuant to an existing shelf registration statement (Form S-3, No. 333-268560).
Investor Verification Checklist
- Verify the final closing date of the offering (expected March 5, 2025).
- Confirm the exact number of shares issued and final net proceeds after all expenses.
- Review the attached Press Release (Exhibit 99.1) for management commentary on the use of proceeds.
- Check subsequent filings for the updated share count and potential dilution impact.
- Review the Placement Agency Agreement (Exhibit 1.1) for specific closing conditions.